EORTC recognized for 2012 ESMO Lifetime Achievement Award
22 Aug 2012
The EORTC is pleased to announce that the following awards will be presented during the ESMO 2012 Opening Ceremony on Friday, 28 September 2012 in Vienna:
ESMO Lifetime Achievement Award
EORTC
Brussels, Belgium
Other ESMO Awards
Hamilton Fairley Award
The recipient of the 2012 Hamilton Fairley Award is Professor Jean-Yves Blay, for his contribution to translational cancer research. Jean-Yves Blay is Professor of Medicine in Medical Oncology and Head of the Medical Oncology Department and the Translational Research Pole at the Centre Léon Bérard of the Université Claude Bernard in Lyon, France. He is one of Europe’s most published lead and co-authors, with more than 350 peer-reviewed papers, principally on sarcomas, GIST and immunotherapy. He writes and lectures on public health issues such as breast and prostate cancer screening programs. He is the past-president of the EORTC and serves as scientific committee member of five cancer centers in France. He has been a reviewer for the Journal of Clinical Oncology, Blood, Cancer, Annals of Oncology, and the European Journal of Cancer.
The Hamilton Fairley Award commemorates one of the founding fathers of Medical Oncology in Europe and is presented to candidates who are internationally recognized for lifetime achievements in science and clinical / laboratory research.
ESMO Award
The 2012 ESMO Award has been bestowed to Professor Ian Tannock for his work on clinical trials for men with metastatic prostate cancer and laboratory-based research on the microenvironment of solid tumors, their resistance to drugs and methods to overcome it. The Award recognizes his tremendous contributions in improving methodology for undertaking clinical trials with emphasis on endpoints of clinical benefit and, at laboratory level, unmasking aspects of solid tumor biology as well as improving outcomes of treatment with chemotherapy.
Based at the University of Toronto, Canada, where he is Professor of Medicine and Medical Biophysics, Prof Tannock has led and helped to design trials that led to the identification of optimal chemotherapy for men with metastatic castration-resistant prostate cancer. Prof. Tannock also serves as Chair of the EORTC Scientific Audit Committee.
The ESMO Award is conferred on an ESMO member who has made an outstanding contribution to the development of oncology worldwide and who recognizes the importance of promoting oncology as a specialty within the international community.
Commemoration of Georges Mathé and presentation of the “Flower of Hope” to Catherine Gaston-Mathé by Martine Piccart
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023